Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP917717.RAR2FVTGN8CRojjjBebn9OnfUf8hpqz08MmfRXc8x2riw130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917717.RAR2FVTGN8CRojjjBebn9OnfUf8hpqz08MmfRXc8x2riw130_provenance.
• NP541056.RABC3Ar2eGncGWd8RXefebJzDKQLIylc_aFFURUFx81_I130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP541056.RABC3Ar2eGncGWd8RXefebJzDKQLIylc_aFFURUFx81_I130_provenance.
• NP539965.RAXm-MdfZ9WMqYPGbS3rJSR6x7EC-CQdr8mSrAr8MsF1w130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP539965.RAXm-MdfZ9WMqYPGbS3rJSR6x7EC-CQdr8mSrAr8MsF1w130_provenance.
• NP647396.RAuz4oZIjWjQzODc_QscjB6Gm4874Qdx4PbQLm4n5eBo0130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647396.RAuz4oZIjWjQzODc_QscjB6Gm4874Qdx4PbQLm4n5eBo0130_provenance.
• NP622514.RAtxerhFupyPoXsI3jJJWySbEystKEhQSmFXifV9mXebI130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622514.RAtxerhFupyPoXsI3jJJWySbEystKEhQSmFXifV9mXebI130_provenance.
• NP867448.RA5kdylGbGxrn3jQ6qMWjtdof2zWknJ8qdmVgd3H6fgHo130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867448.RA5kdylGbGxrn3jQ6qMWjtdof2zWknJ8qdmVgd3H6fgHo130_provenance.
• NP352038.RAxwrKtRsULOASy5KWZ4gREsIsdR8VpCj9ziS3c5gx5fo130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP352038.RAxwrKtRsULOASy5KWZ4gREsIsdR8VpCj9ziS3c5gx5fo130_provenance.
• NP352035.RAUEmjisSRUO1U5_lezPmREyI2EKXY1jJI85f0dagjsY0130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP352035.RAUEmjisSRUO1U5_lezPmREyI2EKXY1jJI85f0dagjsY0130_provenance.
• assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP867522.RAIV8MKwxxxGrkAjqPAdG1X1Mla2OQRhCBW-XwVEwynls130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867522.RAIV8MKwxxxGrkAjqPAdG1X1Mla2OQRhCBW-XwVEwynls130_provenance.
• NP867555.RAPW_6RaRoPUqqDbKKIu6k9ZZQAqDC6H5UKgd0MXGShAM130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867555.RAPW_6RaRoPUqqDbKKIu6k9ZZQAqDC6H5UKgd0MXGShAM130_provenance.
• NP352034.RAKRqftbBeUCgFjqkxCrnBbTeWdEWt0vvDUZTYzBufAQA130_assertion description "[Recombinant soluble human CD39 (solCD39) potently inhibited ex vivo platelet aggregation in response to ADP and reduced cerebral infarct volumes in mice following transient middle cerebral artery occlusion, even when given 3 hours after stroke.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP352034.RAKRqftbBeUCgFjqkxCrnBbTeWdEWt0vvDUZTYzBufAQA130_provenance.